Indeed, studies on their interplay suggest that vWF is a biomarker of cardiovascular disease rather than a classical procoagulant agent, while FVIII levels have been associated with short-term effects such as hyperglycemia and dyslipidemia, independent of vWF, suggesting a predominant procoagulant function of FVIII [31–33]. The gene discussed is VWF; the disease is metabolic syndrome.